Cellenkos gains FDA orphan drug status for CK0804 to treat myelofibrosis
The condition has an estimated prevalence of 25,000 patients in the US and an annual incidence of one to three new cases per 100,000 people. CK0804 is an
Santhera Pharmaceuticals has entered an exclusive licensing agreement with Nxera Pharma for Agamree (Vamorolone) to treat Duchenne muscular dystrophy (DMD) in Australia, Japan, New Zealand, and South Korea.